Lucid Diagnostics Inc. (LUCD) Financial Statements (2024 and earlier)

Company Profile

Business Address 360 MADISON AVENUE
NEW YORK, NY 10017
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18,89622,47453,656
Cash and cash equivalents18,89622,47453,656
Receivables4517200
Inventory, net of allowances, customer advances and progress billings278  
Inventory278  
Prepaid expense60752 
Other undisclosed current assets2,2471,8133,447
Total current assets:22,07324,35657,303
Noncurrent Assets
Operating lease, right-of-use asset1,3072,008 
Property, plant and equipment1,3341,592971
Intangible assets, net (including goodwill)1,4243,445 
Intangible assets, net (excluding goodwill)1,4243,445 
Other noncurrent assets1,1321,108725
Total noncurrent assets:5,1978,1531,696
TOTAL ASSETS:27,27032,50958,999
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,4382,5032,603
Employee-related liabilities557
Accounts payable1,1461,0561,490
Accrued liabilities 3,2921,447556
Debt13,950  
Other liabilities9,339  
Other undisclosed current liabilities1,6555,922 
Total current liabilities:29,3828,4252,603
Noncurrent Liabilities
Liabilities, other than long-term debt1991,037 
Operating lease, liability1991,037 
Total noncurrent liabilities:1991,037 
Other undisclosed liabilities   1,657
Total liabilities:29,5819,4624,260
Equity
Equity, attributable to parent(2,311)23,04754,739
Preferred stock18,625  
Common stock424135
Additional paid in capital129,763121,08196,608
Accumulated deficit(150,741)(98,075)(41,904)
Total equity:(2,311)23,04754,739
TOTAL LIABILITIES AND EQUITY:27,27032,50958,999

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues2,428377500
Cost of revenue  (100,000)(585)
Cost of goods and services sold  (100,000) 
Other undisclosed gross profit  100,000 
Gross profit:2,428377(85)
Operating expenses(50,910)(56,548)(27,334)
Operating loss:(48,482)(56,171)(27,419)
Nonoperating expense
(Other Nonoperating expense)
(4,184)  
Interest and debt expense(26) (659)
Loss from continuing operations before equity method investments, income taxes:(52,692)(56,171)(28,078)
Other undisclosed income from continuing operations before income taxes26  
Loss from continuing operations before income taxes:(52,666)(56,171)(28,078)
Income tax benefit   9,695
Loss from continuing operations:(52,666)(56,171)(18,383)
Loss before gain (loss) on sale of properties:(18,383)
Net loss:(52,666)(56,171)(18,383)
Other undisclosed net loss attributable to parent   (9,695)
Net loss attributable to parent:(52,666)(56,171)(28,078)
Preferred stock dividends and other adjustments   
Net loss available to common stockholders, diluted:(52,666)(56,171)(28,078)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(52,666)(56,171)(18,383)
Comprehensive loss, net of tax, attributable to parent:(52,666)(56,171)(18,383)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: